Brind.

RBC Capital Markets noted disappointing trial results for Compass Pathways, whose drug faces competition from Johnson & Johnson's Spravato.

1 report, 0 independent Updated Jun 23

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

RBC Capital Markets Compass Pathways

Keep exploring

The entities involved

RBC Capital Markets
global investment bank
- WesBanco, led by CEO Jeffrey Jackson and CFO Daniel Weiss, is facing scrutiny from major financial analysts regarding its performance, credit trends, and loan growth sustainability.Fri 03:20
- RBC Capital Markets downgraded Lloyds Banking Group citing increased deposit competition.Tue 10:42
Compass Pathways
mental health care company
- Jefferies Financial Group and Raymond James Financial reaffirmed buy ratings on Compass Pathways stock, which MarketBeat is tracking.Sat 19:36

Coverage

Newest first; wire copies grouped

Jun 23Unknown outlet